EUCTR2017-002821-39-GB进行中（未招募）1 期
Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC - A Phase 2 Study of MCLA-128 combinations in metastatic breast cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Merus N.V
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent before initiation of any study procedures.
- •2. Women with histologically or cytologically confirmed breast cancer with evidence of metastatic or locally advanced disease not amenable to any local therapy with curative intent.
- •2.1 Cohort 1 (MCLA-128 + trastuzumab ± vinorelbine)
- •a) Documented HER2 overexpression/amplification, defined as immunohistochemistry (IHC) 3+ (positive), or IHC 2+ combined with positive fluorescence in situ hybridization (FISH), based on local analysis on the most recent tumor biopsy (preferably metastatic, otherwise primary), either fresh or archival collected within 12 months before screening.
- •b) Documented disease progression (by investigator assessment) on up to a maximum of five lines of HER2-directed therapy administered in the metastatic setting and have progressed on the most recent line. Trastuzumab, pertuzumab and an HER2 antibody drug conjugate (e.g., T-DM1) must have been previously administered in any sequence and in any setting.
- •2.2 Cohort 2 (MCLA-128 + endocrine therapy)
- •a) Documented hormone receptor positive status (estrogen receptor positive [ER+] and/or progesterone receptor positive [PR+]), defined as =1% positive stained cells by local standards, based on local analysis on the most recent tumor biopsy.
- •b) Documented low-level HER2 expression, defined as IHC HER2 1+, or IHC HER2 2+ combined with negative FISH, based on local analysis on a fresh tumour biopsy or an archival biopsy collected within 12 months before screening (preferably metastatic otherwise primary).
- •c) No more than three lines of prior endocrine therapy (aromatase inhibitor or fulvestrant) for metastatic disease, with radiologic or photographic evidence of documented disease progression on the last line, after at least 12 weeks of
- •d) Progression on a cyclin-dependent kinase inhibitor.
- •e) No more than two previous chemotherapy regimens for advanced/metastatic disease.
- •Note: Pre/peri-menopausal women can be enrolled if amendable to be treated with the LHRH agent goserelin. Such patients must have commenced treatment with goserelin or an alternative LHRH agonist at least 4 weeks prior to study entry, and patients who received an alternative LHRH agonist prior to study entry must switch to goserelin for the duration of the trial.
- •3. In Cohort 1, patients must have at least one lesion with measurable disease as defined by RECIST version 1.1. In Cohort 2, patients must have at least one lesion with measurable disease as defined by RECIST version 1.1.
- •Patients with bone-only disease must have lytic or mixed lesions (lytic + sclerotic). For Cohort 2, imaging documenting progression on the last line of hormone therapy must be available for central review.
- •4. Age = 18 years at signature of informed consent.
- •5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •6. Life expectancy of = 12 weeks, as per investigator.
- •7. Left ventricular ejection fraction (LVEF) =50% by echocardiogram or multiple gated acquisition scan.
- •8. Adequate organ function
- •a) Absolute neutrophil count =1.5 x 10(exp)9/L
- •b) Hemoglobin = 9 g/dL
- •c) Platelets = 100 x 10(exp)9/L
- •d) Serum calcium within normal range (or corrected with supplements)
- •e) Alanine aminotransferase (ALT), aspartate aminotransferase (AST) = 2.5 x upper limit of normal (ULN) and total bilirubin = 1.5 x ULN (in cases of liver involvement, ALT/AST = 5 x ULN and total bilirubin within normal ranges will be allowed)
- •f) Serum crea
排除标准
- •1. Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.
- •2. Known leptomeningeal involvement.
- •3. Advanced/metastatic, symptomatic, visceral spread, with a risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver involvement).
- •4. Participation in another interventional clinical trial or treatment with any investigational drug within 4 weeks prior to study entry.
- •5. Any systemic anticancer therapy within 3 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, or anticancer immunotherapies, a washout period of 6 weeks is required. For patients in Cohort 2, this does not apply to the most recently received hormone therapy.
- •6. Major surgery or radiotherapy within 3 weeks of the first dose of study treatment. Patients who received prior radiotherapy to = 25% of bone marrow are not eligible, irrespective of when it was received.
- •7. Persistent grade > 1 clinically significant toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy = grade 1 NCI-CTCAE v. 4.03 is allowed.
- •8. History of hypersensitivity reaction or any toxicity attributed to trastuzumab, murine proteins, or any of the excipients that warranted permanent cessation of these agents (applicable for Cohort 1 only).
- •9. Previous exposure to vinorelbine (applicable for Cohort 1 triplet combination only).
- •10. Exposure to the following cumulative anthracycline doses:
- •a) Doxorubicin or liposomal doxorubicin > 360 mg/m2.
- •b) Epirubicin > 720 mg/m2.
- •c) Mitoxantrone > 120 mg/m2 and idarubicin > 90 mg/m2.
- •d) Other anthracycline at a dose equivalent to > 360 mg/m2 of doxorubicin.
- •e) For patients having received > 1 anthracycline, the cumulative dose must not exceed the equivalent of 360 mg/m2 doxorubicin.
- •11. Chronic use of high-dose oral corticosteroid therapy (>10 mg of prednisone equivalent per day).
- •12. Uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg) or unstable angina.
- •13. History of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia).
- •14. History of myocardial infarction within 6 months of study entry.
- •15. History of prior or concomitant malignancies (other than excised non-melanoma skin cancer or cured in situ cervical carcinoma) within 3 years of study entry.
- •16. Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy.
- •17. Current serious illness or medical conditions including, but not limited to uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders.
- •18. Known HIV, HBV, or HCV infection.
- •19. Pregnant or lactating women; women of childbearing potential must use effective contraception methods (patient and/or partner, e.g., surgical sterilization, a reliable barrier method) prior to study entry, for the duration of study participation, and for 7 months after the last dose of MCLA-128/trastuzumab.
- •20. Patients with only non-measurable lesions other than bone metastasis (e.g., pleural effusion, ascites or other
- •visceral locations
研究者
相似试验
进行中（未招募）
1 期
Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC) : with endocrine therapy for patients with presenting high expression of hormone receptors or with trastuzumab/chemotherapy for patients presenting a high expression of a specific receptor (HER2)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast CancerEUCTR2017-002821-39-BEMerus N.V.120
进行中（未招募）
1 期
Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC) : with endocrine therapy for patients with presenting high expression of hormone receptors or with trastuzumab/chemotherapy for patients presenting a high expression of a specific receptor (HER2)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast CancerEUCTR2017-002821-39-ESMerus N.V.120
进行中（未招募）
1 期
Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC) : with endocrine therapy for patients with presenting high expression of hormone receptors or with trastuzumab/chemotherapy for patients presenting a high expression of a specific receptor (HER2)Metastatic Breast CancerEUCTR2017-002821-39-NLMerus N.V.120
已完成
2 期
Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBCBreast cancerNL-OMON48717Merus N.V.70
进行中（未招募）
1 期
Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC) : with endocrine therapy for patients with presenting high expression of hormone receptors or with trastuzumab/chemotherapy for patients presenting a high expression of a specific receptor (HER2)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast CancerEUCTR2017-002821-39-PTMerus N.V.120